AtriCure, Inc. ATRC
58.10 USD -0.44 (-0.76%)
Nov 9, 2026, 1:48 PM EST
57.18 Day range 59.85
25.36 52-week range 66.02
- YTD
- +46.85%
- 1 year
- +81.26%
News
seekingalpha.com AtriCure: A New Quality Metric Could Put A Clip In Nearly Every Sternotomy AtriCure is shifting from targeting AF patients to all open-heart surgery patients, aiming for broader adoption as a preventive standard of care. Upcoming catalysts include the STS quality metric…
benzinga.com Canaccord Genuity Maintains Buy on AtriCure, Raises Price Target to $67 Canaccord Genuity analyst William Plovanic maintains AtriCure (NASDAQ:ATRC) with a Buy and raises the price target from $55 to $67.
benzinga.com Piper Sandler Reiterates Overweight on AtriCure, Raises Price Target to $70 Piper Sandler analyst Matt O'Brien reiterates AtriCure (NASDAQ:ATRC) with a Overweight and raises the price target from $60 to $70.
benzinga.com Block To Rally Around 54%? Here Are 10 Top Analyst Forecasts For Wednesday Analysts raised targets for FRSH, EW, ATRC, SUPN and DUOL; cut targets for FLG and AMD. EW was upgraded, while FLG was downgraded.
benzinga.com AtriCure Analysts Boost Their Forecasts After Better-Than-Expected Q3 Results AtriCure, Inc. (NASDAQ:ATRC) on Tuesday posted upbeat results for the third quarter.
benzinga.com AtriCure Analysts Boost Their Forecasts After Better-Than-Expected Q3 Results AtriCure beat Q3 estimates, raised FY2026 EPS and sales guidance, and saw analysts lift price targets to $70; shares fell 2%.
benzinga.com Needham Maintains Buy on AtriCure, Raises Price Target to $70 Needham analyst Mike Matson maintains AtriCure (NASDAQ:ATRC) with a Buy and raises the price target from $64 to $70.
benzinga.com BTIG Maintains Buy on AtriCure, Raises Price Target to $70 BTIG analyst Marie Thibault maintains AtriCure (NASDAQ:ATRC) with a Buy and raises the price target from $63 to $70.
seekingalpha.com AtriCure, Inc. (ATRC) Q3 2026 Earnings Call Transcript AtriCure, Inc. ( ATRC ) Q3 2026 Earnings Call November 3, 2026 4:30 PM EST Company Participants Michael H. Carrel - CEO, President & Director Angela Wirick - Chief Financial Officer Conference Call…
marketbeat.com What AtriCure (ATRC) Said on Its Q3 Earnings Call AtriCure NASDAQ: ATRC reported third-quarter 2026 revenue of $154.5 million, up 15% from a year earlier, as growth in its U.S. open ablation, appendage management and pain management businesses…
zacks.com Compared to Estimates, AtriCure (ATRC) Q3 Earnings: A Look at Key Metrics The headline numbers for AtriCure (ATRC) give insight into how the company performed in the quarter ended September 2026, but it may be worthwhile to compare some of its key metrics to Wall Street…
zacks.com AtriCure (ATRC) Beats Q3 Earnings and Revenue Estimates AtriCure (ATRC) came out with quarterly earnings of $0.17 per share, beating the Zacks Consensus Estimate of $0.01 per share. This compares to a loss of $0.01 per share a year ago.
benzinga.com AtriCure Q3 2026 Earnings Call Transcript AtriCure (NASDAQ:ATRC) reported third-quarter financial results on Tuesday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to you by…- benzinga.com AtriCure Q3 Adj. EPS $0.17 Beats $(0.05) Estimate, Sales $154.450M Beat $151.217M Estimate AtriCure (NASDAQ:ATRC) reported quarterly earnings of $0.17 per share which beat the analyst consensus estimate of $(0.05) by 440 percent. This is a 1800 percent increase over losses of $(0.01) per…
benzinga.com AtriCure Raises FY2026 Adj EPS Guidance from $0.24-$0.32 to $0.40-$0.46 vs $0.15 Est; Raises FY2026 Sales Guidance from $602.000M-$610.000M to $606.000M-$610.000M vs $606.219M Est AtriCure (NASDAQ:ATRC) raises FY2026 Adj EPS guidance from $0.24-$0.32 to $0.40-$0.46 vs $0.15 analyst estimate. Raises FY2026 sales outlook from $602.000 million-$610.000 million to $606.000…
businesswire.com AtriCure Reports Third Quarter 2026 Financial Results MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and…- benzinga.com Citizens Maintains Market Outperform on AtriCure, Raises Price Target to $68 Citizens analyst Daniel Stauder maintains AtriCure (NASDAQ:ATRC) with a Market Outperform and raises the price target from $52 to $68.
benzinga.com BTIG Maintains Buy on AtriCure, Raises Price Target to $63 BTIG analyst Ryan Zimmerman maintains AtriCure (NASDAQ:ATRC) with a Buy and raises the price target from $55 to $63.
benzinga.com Abbott To Rally Over 31%? Here Are 10 Top Analyst Forecasts For Friday Analysts raised targets for ACN, SYNA, ATRC and MPC; cut targets for CSX, NKE, MKC and FHTX, with ATRC downgraded to Hold.
benzinga.com This AST SpaceMobile Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday Analysts downgraded FHTX, BUSE, ASTS, ATRC and EQBK; targets fell for BUSE, ASTS and EQBK but rose for ATRC.
benzinga.com Freedom Capital Markets Downgrades AtriCure to Hold, Raises Price Target to $57 Freedom Capital Markets analyst Keith Hinton downgrades AtriCure (NASDAQ:ATRC) from Buy to Hold and raises the price target from $43 to $57.- benzinga.com Bloom Energy, Illumina, and Everpure Set to Join S&P 500; Others to Join S&P 100, S&P MidCap 400, and S&P SmallCap 600 https://www.spglobal.com/spdji/en//documents/indexnews/announcements/20260904-1484999/1484999_shuffle5461-sept2026.pdf
benzinga.com Sirius XM, Dell, Ollie's Bargain Outlet And Other Big Stocks Moving Higher On Wednesday U.S. stocks rose; Sirius XM jumped 5.5% after Deutsche Bank’s upgrade, while GitLab, Dell and other stocks rallied on strong results.
benzinga.com Salesforce To Rally More Than 16%? Here Are 10 Top Analyst Forecasts For Wednesday Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Cantor…- benzinga.com Needham Maintains Buy on AtriCure, Raises Price Target to $64 Needham analyst Mike Matson maintains AtriCure (NASDAQ:ATRC) with a Buy and raises the price target from $45 to $64.
benzinga.com Piper Sandler Maintains Overweight on AtriCure, Raises Price Target to $60 Piper Sandler analyst Matt O'Brien maintains AtriCure (NASDAQ:ATRC) with a Overweight and raises the price target from $50 to $60.
benzinga.com Analog Devices To Rally Around 81%? Here Are 10 Top Analyst Forecasts For Monday Top analysts change outlook on top names. See all rating changes, including upgrades/downgrades, on analyst ratings page. Follow other analysts.- benzinga.com BTIG Maintains Buy on AtriCure, Raises Price Target to $55 BTIG analyst Marie Thibault maintains AtriCure (NASDAQ:ATRC) with a Buy and raises the price target from $45 to $55.
benzinga.com Top 3 Health Care Stocks That May Implode This Month RSI warning: 3 overbought health care stocks could be flashing a real warning to investors with high momentum trading preferences- benzinga.com UBS Maintains Buy on AtriCure, Lowers Price Target to $50 UBS analyst Priya Sachdeva maintains AtriCure (NASDAQ:ATRC) with a Buy and lowers the price target from $55 to $50.
benzinga.com AtriCure Reports Q2 2026 Results: Full Earnings Call Transcript AtriCure (NASDAQ:ATRC) reported second-quarter financial results on Thursday. The transcript from the company's second-quarter earnings call has been provided below. This transcript is brought to you…- benzinga.com AtriCure Q2 Adj. EPS $0.18 Beats $0.00 Estimate, Sales $153.600M Beat $151.842M Estimate AtriCure (NASDAQ:ATRC) reported quarterly earnings of $0.18 per share which beat the analyst consensus estimate of $0.00 by Infinity percent. This is a 1000 percent increase over losses of $(0.02)…
- benzinga.com AtriCure Raises FY2026 Adj EPS Guidance from $0.00-$0.04 to $0.24-$0.32 vs $0.06 Est; Raises FY2026 Sales Guidance from $600.000M-$610.000M to $602.000M-$610.000M vs $604.990M Est AtriCure (NASDAQ:ATRC) raises FY2026 Adj EPS guidance from $0.00-$0.04 to $0.24-$0.32 vs $0.06 analyst estimate. Raises FY2026 sales outlook from $600.000 million-$610.000 million to $602.000…
benzinga.com Earnings Scheduled For July 23, 2026 Companies Reporting Before The Bell • Altisource Portfolio (NASDAQ:ASPS) is estimated to report quarterly earnings at $0.18 per share on revenue of $42.90 million. • Dime Commercial (NYSE:DCOM) is…
benzinga.com Canaccord Genuity Maintains Buy on AtriCure, Raises Price Target to $55 Canaccord Genuity analyst William Plovanic maintains AtriCure (NASDAQ:ATRC) with a Buy and raises the price target from $53 to $55.
benzinga.com AtriCure Q1 2026 Earnings Call Transcript - benzinga.com AtriCure Lowers FY2026 Adj EPS Guidance from $0.09-$0.15 to $0.00-$0.04 vs $0.07 Est; Affirms FY2026 Sales Guidance of $600.000M-$610.000M vs $604.053M Est 2026 Financial GuidanceFull year 2026 revenue is projected to be approximately $600 million to $610 million, and management also projects full year 2026 Adjusted EBITDA of approximately $80 million…
- benzinga.com AtriCure Q1 Adj. EPS $0.00 Beats $(0.06) Estimate, Sales $141.249M Beat $139.812M Estimate AtriCure (NASDAQ:ATRC) reported quarterly earnings of $0.00 per share which beat the analyst consensus estimate of $(0.06) by 100 percent. This is a 100 percent increase over losses of $(0.14) per…
- benzinga.com Earnings Scheduled For May 5, 2026
benzinga.com This Masimo Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday - benzinga.com Earnings Scheduled For February 17, 2026
benzinga.com Earnings Scheduled For October 29, 2025 
benzinga.com Why LendingClub Shares Are Trading Higher By Around 23%; Here Are 20 Stocks Moving Premarket 
benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session - benzinga.com Earnings Scheduled For July 29, 2025
- benzinga.com Earnings Scheduled For April 29, 2025
- benzinga.com Earnings Scheduled For February 12, 2025
- benzinga.com Snap Posts Upbeat Earnings, Joins Unisys, AtriCure, Garmin And Other Big Stocks Moving Higher On Wednesday
- benzinga.com Earnings Scheduled For February 15, 2024 Companies Reporting Before The Bell • Cognex (NASDAQ:CGNX) is estimated to report quarterly earnings at $0.10 per share on revenue of $188.59 million.
- benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session